Intrauterine Contraceptive Devices Market Size and Share
Market Overview
| Study Period | 2019 - 2030 |
|---|---|
| Market Size (2025) | USD 5.62 Billion |
| Market Size (2030) | USD 6.79 Billion |
| Growth Rate (2025 - 2030) | 3.86% CAGR |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
| Market Concentration | Medium |
Major Players
*Disclaimer: Major Players sorted in no particular order Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0. |
|
Intrauterine Contraceptive Devices Market Analysis by Mordor Intelligence
The intrauterine contraceptive devices market is valued at USD 5.62 billion in 2025 and is forecast to reach USD 6.79 billion by 2030, expanding at a 3.86% CAGR. Growth is supported by rapid product innovation, rising demand from younger cohorts delaying childbirth, and expanding NGO procurement that eases affordability constraints. Copper IUDs still command most revenue because of long product life and low unit cost, yet hormonal devices are closing the gap as clinical data confirm their additional therapeutic benefits. Manufacturers are accelerating R&D on flexible frames and lower-copper or alternative-metal systems to reduce side effects—an essential differentiator in markets where discomfort and bleeding remain leading causes of discontinuation. Political headwinds in several U.S. states and cultural resistance in parts of Africa and the Middle East threaten adoption, but coordinated public-sector and NGO distribution programs continue to widen access, particularly in underserved rural areas.
Key Take Aways
- By product type, copper IUDs led with 65.1% intrauterine contraceptive devices market share in 2024, while hormonal systems are projected to expand at 6.25% CAGR through 2030.
- By age group, users aged 25-34 accounted for 62.6% share of the intrauterine contraceptive devices market size in 2024; the under-20 cohort is set to grow fastest at 7.18% CAGR to 2030.
- By end user, hospitals held 55.0% revenue share in 2024; community health centers post the strongest growth at 6.15% CAGR over the forecast period.
- By distribution channel, public procurement retained 51.0% share of the intrauterine contraceptive devices market size in 2024, whereas NGO-funded channels are growing at 7.63% CAGR.
- By geography, Asia-Pacific dominated with a 34.9% share in 2024; the Middle East and Africa are the fastest-growing regions at a 5.75% CAGR.
Global Intrauterine Contraceptive Devices Market Trends and Insights
Drivers Impact Analysis
| Driver | (~) % Impact on CAGR Forecast | Geographic Relevance | Impact Timeline |
|---|---|---|---|
| Technological innovation reduces side effects | +0.8% | Global (higher in high-income markets) | Medium term (2-4 years) |
| Rising demand for long-acting reversible contraceptives | +0.7% | North America, Europe, urban Asia-Pacific | Short term (≤ 2 years) |
| Government initiatives and support policies | +0.6% | Emerging Asia-Pacific, Latin America | Medium term (2-4 years) |
| Favorable recommendations from global health organizations | +0.6% | Global | Short term (≤ 2 years) |
| Increasing trend of delayed childbirth | +0.5% | North America, Europe, urban Asia | Long term (≥ 4 years) |
| Expansion of NGO-led social-marketing programs | +0.6% | Middle East and Africa, rural Asia, Latin America | Medium term (2-4 years) |
| Source: Mordor Intelligence | |||
Technological Innovation Leading to Effective Contraceptives and Fewer Side Effects
New materials and engineering approaches are redefining copper devices. The FDA-cleared MIUDELLA uses a nitinol frame and 50% less copper yet keeps 99% efficacy, easing pain and heavy bleeding previously linked to conventional designs. Research teams are testing flexible iron-based frames that could cut inflammatory responses while safeguarding contraceptive strength. These improvements matter most in markets where fear of adverse events still deters uptake, and they give suppliers an edge with premium pricing tied to better user comfort.
Rising Demand for Long-Acting Reversible Contraceptives (LARCs)
Healthcare providers are steering patients toward devices that need no daily action and have <1% first-year failure rates.[1]Centers for Disease Control and Prevention, “U.S. Selected Practice Recommendations for Contraceptive Use,” CDC, cdc.gov Women aged 25-34 already represent nearly two-thirds of IUD use, mirroring their desire for long protection while postponing pregnancies. Updated U.S. practice guidelines in 2024 place LARCs first in counseling scripts, a move likely to ripple into other national protocols.
Government Initiatives and Support Policies
Public procurement programs are scaling in Kenya, Nigeria and Vietnam, combining free device provision, provider training and supply-chain upgrades that jointly address cost and access barriers. Kenya’s public hospitals began offering hormonal IUDs without charge in 2024, widening availability beyond private clinics.[2]United Nations Population Fund, “UNFPA Supplies Performance Measurement Report 2023,” UNFPA, unfpa.org Similar models in Nigeria aim to raise modern-method prevalence to 27% by 2026.
Favorable Recommendations from Global Health Organizations
The World Health Organization includes IUDs in essential contraceptive care and offers technical toolkits to help ministries embed them into national formularies.[3]World Health Organization, “Contraception,” WHO, who.intThe International Contraceptive Access Foundation has donated more than 250,000 hormonal devices to low-resource settings, linking supply to hands-on provider mentoring.
Restraints Impact Analysis
| Restraints | (~) % Impact on CAGR Forecast | Geographic Relevance | Impact Timeline |
|---|---|---|---|
| Side effects and complications | –0.8% | Global (more acute where specialist care is scarce) | Short term (≤ 2 years) |
| Cultural & religious opposition plus low awareness | –1.1% | Middle East, Africa, rural Asia, conservative U.S. regions | Long term (≥ 4 years) |
| Skilled provider shortage for insertions | –0.7% | Emerging markets, remote areas worldwide | Medium term (2-4 years) |
| High upfront device and insertion cost | –0.6% | Low-income countries, uninsured groups in high-income markets | Short term (≤ 2 years) |
| Source: Mordor Intelligence | |||
Risk of Side Effects and Complications
Heavy bleeding, cramping and misplaced insertions remain top deterrents. A 2024 International Journal of Pharmaceutics study links polymer formulation and curing conditions to variable LNG release, influencing adverse events.[4]International Journal of Pharmaceutics, “Drug Content Uniformity and Release Rate of Levonorgestrel Systems,” sciencedirect.com Provider skill also matters; malposition rates are nearly double when generalists insert devices versus obstetric-gynecology specialists.
Cultural and Religious Opposition Coupled with Lack of Awareness
Misconceptions that IUDs cause abortion or permanent infertility persist in parts of sub-Saharan Africa and the Middle East. Community surveys in Ethiopia’s Afar and Somali regions found religious concerns to be the leading barrier to modern contraceptive use. Comparable narratives shape recent U.S. state restrictions on Medicaid coverage for IUDs, underscoring the influence of ideology on policy and personal choice.
Segment Analysis
By Type: Copper IUDs Dominate While Hormonal Systems Gain Momentum
Copper devices generated 65.1% of the intrauterine contraceptive devices market revenue in 2024, reflecting their long clinical track record and lower per-unit price. Hormonal systems, however, will record a 6.25% CAGR to 2030, narrowing the gap as research underscores benefits in menstrual regulation and dysmenorrhea management. The February 2025 approval of MIUDELLA featuring a flexible nitinol frame and reduced copper illustrates how engineering refinements address historic pain and bleeding complaints, boosting acceptance in regions where side effects once limited uptake. Academic teams pursuing iron-based frames highlight a potential next class of non-hormonal products with softer inflammatory profiles that could lure users who previously avoided copper models.
Manufacturers are also enhancing supply-chain efficiency to lower production costs, a change that supports public-sector tenders seeking bulk volumes at modest price points. Given these trends, copper units will remain volume leaders, but hormonal devices are set to capture incremental value share as higher reimbursement ceilings in Europe and North America favor premium pricing.
Note: Segment shares of all individual segments available upon report purchase
By Age Group: 25-34 Years Segment Drives Volume While Under-20 Shows Highest Growth
Women aged 25-34 contribute 62.6% of the intrauterine contraceptive devices market size, aligning long-acting protection with peak career building years. Survey data indicate that immediate reversibility appeals strongly to this cohort once family-building decisions shift. In contrast, adolescents under 20 log the highest forecast CAGR at 7.18% through 2030 after medical bodies clarified eligibility and safety parameters. Policy moves that permit confidential youth access and school-based counseling also influence uptake. Meanwhile, uptake among women above 35 remains steady as many seek reliable spacing after completing families but avoid permanent sterilization.
By End User: Hospitals Lead While Community Health Centers Expand Rapidly
Hospitals account for 55.0% of intrauterine contraceptive devices market share in 2024 thanks to bundled maternity services that include bedside postpartum insertion. Cost modeling shows hospitals save USD 211,100 per 1,000 births by preventing unintended pregnancies when they offer immediate placement. Community health centers, expanding at 6.15% CAGR, are broadening rural and low-income access but still face supply hurdles, from device funding gaps to inadequate on-site training. Specialist OB-GYN clinics retain a loyal base among privately insured women, whereas family-planning centers continue to serve as safety-net providers for uninsured populations.
Note: Segment shares of all individual segments available upon report purchase
By Distribution Channel: Public Sector Dominates While NGO Programs Show Highest Growth
Government procurement captured 51.0% of intrauterine contraceptive devices market revenue in 2024 as ministries incorporate long-acting methods into essential drug lists. Yet funding gaps remain; 51% of reporting countries disclosed shortfalls between planned and actual contraceptive budgets in the latest USAID security metrics. NGO channels, growing at 7.63% CAGR, fill many of these gaps by subsidizing devices and leveraging social-marketing to build demand among low-income segments. Private retail and telehealth are expanding in urban markets but remain constrained by the clinical insertion requirement.
Geography Analysis
Asia-Pacific owns 34.9% of intrauterine contraceptive devices market revenue because of large user bases and active family-planning programs. China’s relaxation of birth limits fuels demand for reversible methods, while India’s domestic suppliers scale up to meet rising urban uptake. A Delhi study found 73% of couples using modern contraception, with IUDs gaining traction among educated women eyeing career continuity. Japan and South Korea show slower uptake but higher unit values per device, reflecting a preference for newer hormonal systems.
Middle East and Africa is the fastest-growing region at 5.75% CAGR as multilateral initiatives expand product availability and provider capacity, though cultural resistance still dampens absolute penetration. UNFPA’s Supplies Partnership now covers 54 countries, with IUD availability at secondary care sites rising to 65% in 2024. Sub-Saharan Africa’s average modern-method prevalence sits at 28.4%, and only 9.6% of women use long-acting methods, highlighting vast untapped potential as training and outreach progress.
North America and Europe maintain high value shares, driven by premium products and reimbursement frameworks that absorb higher device costs. In the U.S., regulatory volatility has emerged as a wildcard, with several states debating coverage restrictions that could blunt future growth. Latin America’s moderate expansion is led by Brazil and Mexico, where blended public-private programs ease budget pressures and raise awareness through mobile clinics and televised campaigns.
Competitive Landscape
The arena is moderately fragmented. Bayer AG, CooperSurgical and Organon leverage extensive global distribution and brand equity, while niche players such as Sebela Women’s Health capture attention with product differentiators that reduce user discomfort. CooperSurgical’s Paragard remains the only FDA-approved non-hormonal IUD in the U.S., underpinning stable cash flows. Sebela’s MIUDELLA launch demonstrates how innovation can carve share even in mature markets, prompting incumbents to invest in frame flexibility and metal-surface optimization. Academic-industry collaboration is intensifying around alternative metals and dual-protection concepts that incorporate antiretroviral release for HIV prevention.
Regional producers, notably in India and China, undercut global brands on price, strengthening their grip on public tenders. Strategic acquisitions and co-manufacturing agreements are proliferating as firms seek cost synergies and faster market entry.
Intrauterine Contraceptive Devices Industry Leaders
-
Abbvie Inc (Allergan Plc)
-
Bayer AG
-
CooperSurgical Inc.
-
DKT International
-
EUROGINE, S.L
- *Disclaimer: Major Players sorted in no particular order
Recent Industry Developments
- February 2025: Sebela Women’s Health received FDA clearance for MIUDELLA, the first new hormone-free copper system in over four decades.
- January 2025: Sebela reported Phase 3 data for its Copper 175 mm² IUD, posting a 1-year Pearl Index of 0.94.
- December 2024: The Cooper Companies highlighted Paragard’s strategic role in the women’s health portfolio in its annual report
- September 2024: Kenya began nationwide free hormonal IUD distribution through public hospitals.
- Jul 2024: Western University researchers unveiled an iron-frame IUD prototype with reduced inflammatory reaction.
Research Methodology Framework and Report Scope
Market Definitions and Key Coverage
Our study defines the intrauterine contraceptive devices market as the annual revenue generated from new copper and hormonal systems that are inserted into the uterus for long-acting pregnancy prevention, across all clinical end-user channels.
According to Mordor Intelligence, refurbished devices, diaphragms, contraceptive implants, and emergency-use copper IUDs sold outside regular family-planning settings are excluded.
Segmentation Overview
- By Type
- Hormonal Intrauterine System (LNG-IUS)
- Copper Intrauterine Device
- By Age Group
- <20 Years
- 20-24 Years
- 25-34 Years
- 35-44 Years
- >44 Years
- By End User
- Hospitals
- Gynecology and Obstetrics Clinics
- Community Health Centers
- Family Planning & Sexual Health Centers
- Other Ambulatory Settings
- By Distribution Channel
- Public Sector Procurement
- Private Sector (Retail & Clinics)
- NGO and Donor-Funded Programs
- Online/Pharmacy Retail
- Geography
- North America
- United States
- Canada
- Mexico
- Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- Middle East and Africa
- GCC
- South Africa
- Rest of Middle East and Africa
- South America
- Brazil
- Argentina
- Rest of South America
- North America
Detailed Research Methodology and Data Validation
Primary Research
Mordor analysts interviewed obstetricians, hospital procurement leads, and NGO supply-chain managers across North America, India, Nigeria, and Brazil. These conversations clarified real-world insertion fees, public versus private mix shifts, copper to hormonal conversion rates, and expected device lifespans, giving us confidence to refine model drivers surfaced during desk work.
Desk Research
We began with open datasets from the WHO family-planning dashboard, UNFPA contraceptive commodity procurement files, the CDC's National Survey of Family Growth, Eurostat birth-control sales codes, and Demographic & Health Surveys, which revealed age-cohort adoption, public-sector tender values, and unit imports. Company 10-Ks, FDA device registries, and trade-association briefs (FIGO, ACOG) anchored average selling prices and technology refresh cycles. Paid look-ups on D&B Hoovers and Dow Jones Factiva filled recent revenue splits and launch timelines. The sources cited here are illustrative; many additional references were reviewed during validation.
Market-Sizing & Forecasting
A top-down demand pool was built from the female reproductive-age population, modern-method prevalence, and IUD penetration ratios, which are then multiplied by weighted ASPs. Select bottom-up roll-ups of major suppliers' device shipments tested total plausibility. Key variables like procurement budgets, postpartum insertion policies, hormonal system price premiums, and region-specific discontinuation rates power a multivariate regression that projects value through 2030. Gap years in shipment disclosures are bridged with scenario curves aligned to interview consensus.
Data Validation & Update Cycle
Outputs pass three-layer checks: automatic variance flags, senior analyst peer review, and quarterly re-contacts when policy shocks or recalls arise. Reports refresh every twelve months; interim patches are issued if material events shift our baseline.
Why Our Intrauterine Contraceptive Devices Baseline Commands Reliability
Published estimates diverge because firms frame scope, price, and refresh cadence differently. Mordor's disciplined exclusions, dual-track modeling, and annual update rhythm keep our numbers grounded for planners. Scope drift, mixed device baskets, and currency timing explain most gaps.
Benchmark comparison
| Market Size | Anonymized source | Primary gap driver |
|---|---|---|
| $5.62 B (2025) | Mordor Intelligence | - |
| $4.30 B (2025) | Global Consultancy A | Leaves NGO volumes out; uses ex-factory pricing. |
| $6.47 B (2024) | Industry Journal B | Combines IUDs with subdermal implants, inflating base year. |
| $4.56 B (2024) | Regional Consultancy C | Models only copper devices in revenue pool. |
The comparison shows that once differing device mixes and channel coverages are stripped away, Mordor's balanced, transparent baseline, anchored to clearly cited variables and repeatable steps, remains the dependable reference point for strategy teams.
Key Questions Answered in the Report
1. What is the current size of the intrauterine contraceptive devices market?
The intrauterine contraceptive devices market is valued at USD 5.62 billion in 2025 and is projected to reach USD 6.79 billion by 2030.
2. Which product type holds the largest share of the market?
Copper IUDs dominate with 65.1% intrauterine contraceptive devices market share in 2024, reflecting their lower cost and long clinical track record.
3. Which age group generates the highest demand for IUDs?
Women aged 25-34 account for 62.6% of the intrauterine contraceptive devices market size, driven by the need for long-acting but reversible protection during peak career-building years.
Which region has the biggest share in Global Intrauterine Contraceptive Devices (IUD) Market?
In 2025, the North America accounts for the largest market share in Global Intrauterine Contraceptive Devices (IUD) Market.
4. Why are hormonal IUDs growing faster than copper IUDs?
Hormonal systems are forecast to expand at a 6.25% CAGR to 2030 because they reduce menstrual bleeding and cramping while maintaining >99% effectiveness, making them attractive in markets that can absorb their higher price.
5. Which geographic region is growing the fastest?
Middle East & Africa is the fastest-growing region, advancing at a 5.75% CAGR through 2030 thanks to UN-backed supply programs and improving healthcare infrastructure, despite cultural barriers.
6. How are NGO programs influencing market growth?
NGO-funded channels are expanding at a 7.63% CAGR by subsidizing devices and running social-marketing campaigns that improve awareness and affordability in underserved areas.
Page last updated on:
